Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for Visual Hallucinations in Parkinson's Disease
NCT01856738Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2013
- Primary completion
- Sep 2018
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of rivastigmine in Parkinson's disease (PD), sponsored by Amsterdam University Medical Center. Started Nov 2013; status: terminated.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01856738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856738.